tirzepatide heart failure trial Lilly says weight loss drug cuts risk by 38% in tirzepatide cardiovascular outcomes trial 2024

Diabetes Obes Metab 2022, 24(7): 1288-1299

About a third of burn patients benefit from using GHK-Cu, according to Cyprus studies on mice

Int J Mol Med2022 Mar;49(3):34

Enrolled patients had a baseline or recent liver biopsy showing clinically significant MASLD (metabolic dysfunction-associated steatotic liver disease), defined as MASH with fibrosis stage 2 or 3 and a non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS) 4 with a score of 1 or more in steatosis, lobular inflammation, and hepatocyte ballooning

Occasionally you can find the best price on Amazon, but buying direct unlocks the impressive money-back guarantee

In humans, it has simply never been tested